Pharmacology and mechanisms of action of new oral anticoagulants

Fundamental and Clinical Pharmacology

Volumn 29, Issue 1, 2015, Pages 10-20

  Salem, Joe Elie ^a,b,c   Sabouret, Pierre ^b   Funck Brentano, Christian ^a,b,c   Hulot, Jean Sebastien ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Anticoagulant; Apixaban; Dabigatran; Edoxaban; Heparin; Pharmacology; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; BRAIN HEMORRHAGE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; ATRIAL FIBRILLATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS;

EID: 84921065018     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12091     Document Type: Review

References (55)

1. Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. (2008) 26 2765-2775.
2. Lassen M.R., Ageno W., Borris L.C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. (2008) 26 2776-2786.
3. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. (2009) 12 1139-1151.
4. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. (2011) 9 806-817.
5. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. (2011) 10 883-891.
6. Granger C.B., Alexander J.H., McMurray J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. (2011) 11 981-992.
7. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. (2013) 22 2093-2104.
8. EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. (2010) 26 2499-2510.
9. EINSTEIN-PE Investigators, Büller H.R., Prins M.H., Lensin A.W.A. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. (2012) 14 1287-1297.
10. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. (2013) 8 699-708.
11. Hokusai-VTE Investigators, Büller H.R., Décousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. (2013) 15 1406-1415.
12. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. (2012) 1 9-19.
13. Rezaie A.R. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood (2001) 8 2308-2313.
14. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. (2005) 12 873-880.
15. Perzborn E., Strassburger J., Wilmen A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. (2005) 3 514-521.
16. Depasse F., Busson J., Mnich J. et al. Effect of BAY 59-7939- a novel, oral, direct Factor Xa inhibitor-on clot-bound Factor Xa activity in vitro. J. Thromb. Haemost. (2005) 3 Abstract P1104.
17. Pinto D.J.P., Orwat M.J., Koch S., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. (2007) 22 5339-5356.
18. Walenga J.M., Hoppensteadt D., Iqbal O. et al. The oral, direct factor Xa inhibitor BAY 59-7939 does not cross-react with antiheparin/ PF4 (heparin-induced thrombocytopenia) antibodies. Blood (American Society of Hematology Annual Meeting Abstracts) (2005) 11 Abstract P1883.
19. Buller H.R., Lensing A.W.A., Prins M.H., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood (2008) 6 2242-2247.
20. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effects of single-dose BAY 59-7939 - an oral, direct Factor Xa inhibitor - in subjects with extreme body weight. Blood (2005) 106 Abstract P1872.
21. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. (2007) 2 218-226.
22. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J. Clin. Pharmacol. (2006) 5 549-558.
23. Daily Med, Current Medication Information, Apixaban http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0 [accessed 26 June 2014].
24. Bathala M.S., Masumoto H., Oguma T., He L., Lowrie C., Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab. Dispos. (2012) 12 2250-2255.
25. Bayer Schering Pharma AG. Xarelto summary of product characteristics. http://www.xarelto.com/html/downloads/2013-05_XRL_SPC_final_low.pdf [accessed 26 June 2014].
26. Daily Med, Current Medication Information, Dabigatran Etexilate Mesylate, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 [accessed 26 June 2014].
27. Eikelboom J.W., Connolly S.J., Brueckmann M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. (2013) 13 1206-1214.
28. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. (2012) 5 397-402.
29. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. (2011) 8 699-708.
30. Ru San T., Chan M.Y.Y., Wee Siong T. et al. Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 108983.
31. Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2 131-136.
32. Piccini J.P., Stevens S.R., Lokhnygina Y., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J. Am. Coll. Cardiol. (2013) 19 1998-2006.
33. Flaker G., Lopes R.D., Al-Khatib S.M., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J. Am. Coll. Cardiol. (2014) 11 1082-1087.
34. Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur. Heart J. (2013) 27 2094-2106.
35. Ezekowitz M.D., Cappato R., Klein A.L., et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with nonvalvular atrial fibrillation scheduled for cardioversion trial: a comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. Am. Heart J. (2014) 5 646-652.
36. Steiner T., Böhm M., Dichgans M., et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin. Res. Cardiol. (2013) 6 399-412.
37. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. (2005) 4 412-421.
38. Mueck W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int. J. Clin. Pharmacol. Ther. (2007) 6 335-344.
39. Samama M.M., Amiral J., Guinet C., Perzborn E., Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb. Haemost. (2010) 5 1078-1079.
40. Samama M.M., Contant G., Spiro T.E., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb. Haemost. (2012) 2 379-387.
41. Barrett Y.C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost. (2010) 6 1263-1271.
42. Bauer K.A. Reversal of antithrombotic agents. Am. J. Hematol. (2012) 87(Suppl 1) S119-S126.
43. Lu G., DeGuzman F.R., Hollenbach S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. (2013) 4 446-451.
44. Siegal D.M., Crowther M.A. Acute management of bleeding in patients on novel oral anticoagulants. Eur. Heart J. (2013) 7 489-498b.
45. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 14 1573-1579.
46. Marlu R., Hodaj E., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. (2012) 2 217-224.
47. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb. Haemost. (2013) 4 596-605.
48. Cotton B.A., McCarthy J.J., Holcomb J.B. Acutely injured patients on dabigatran. N. Engl. J. Med. (2011) 21 2039-2040.
49. Van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. (2010) 6 1116-1127.
50. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2 randomized dose-ranging study (EXPLORE-Xa) Eur. Heart J. (2013) 34 1498-1505.
51. Daily Med, Current Medication Information, Rivaroxaban, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610 [accessed 26 June 2014].
52. Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J. Clin. Pharmacol. (2010) 50 743-753.
53. Samama M.M., Mendell J., Guinet C., Le Flem L., Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb. Res. (2012) 4 77-82.
54. Fukuda T., Honda Y., Kamisato C., Morishima Y., Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb. Haemost. (2012) 2 253-259.
55. European Medecines Agency, Summary of product characteristics, Rivaroxaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp%26mid=WC0b01ac058001d124 [accessed 26 June 2014].